91 results match your criteria Cancer treatment and research communications[Journal]


Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction.

Cancer Treat Res Commun 2020 Jun 27;24:100187. Epub 2020 Jun 27.

Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

Background: Chemoradiotherapy is standard treatment for localized oesophageal cancer unsuitable for surgery. We aimed to evaluate the efficacy of cetuximab in combination with chemoradiotherapy.

Methods: This non-randomised multicentre phase II trial recruited patients aged 18-75 with WHO performance status 0-2 having squamous cell carcinoma or adenocarcinoma in the oesophagus or gastro-oesophageal junction, T2-4, N0-3, M0 not suitable for surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100187DOI Listing

Antibody selection influences the detection of AR-V7 in primary prostate cancer.

Cancer Treat Res Commun 2020 Jun 23;24:100186. Epub 2020 Jun 23.

Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, Heidelberg, D-69120, Germany; Department of Urology, University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 110, Heidelberg, D-69120, Germany. Electronic address:

Background: The androgen receptor (AR) splice variant V7 (AR-V7) is an emerging marker to aid clinical decision-making in patients with castration-resistant prostate cancer (CRPC). A number of studies have shown that a subset of patients also express AR-V7 in the primary tumor. These findings have recently been challenged by a study showing that AR-V7 becomes only detectable in CRPC but is virtually absent in castration-naïve prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100186DOI Listing

Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience.

Cancer Treat Res Commun 2020 Jun 27;24:100188. Epub 2020 Jun 27.

Medical Oncology, Royal Marsden Hospital, Royal Marsden Hospital, Downs Road, Sutton SM25PT, United Kingdom. Electronic address:

Background: Ado-trastuzumab emtansine (T-DM1) is standard of care for patients with advanced HER2+ breast cancer who relapse within 6 months of adjuvant trastuzumab or progress on first-line anti-HER2 therapy. We evaluated its safety and efficacy in our real-world population.

Methods: We identified patients on T-DM1 from 01/01/2014 to 12/03/2018 from our electronic records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100188DOI Listing

The impact of smoking on adjuvant breast cancer radiation treatment: A systematic review.

Cancer Treat Res Commun 2020 Jun 20;24:100185. Epub 2020 Jun 20.

Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Background: The influence of cigarette smoking on cancer risk has been well-studied. Similarly, exposure to ionizing radiation from radiotherapy (RT) can produce detrimental effects on an individual's health. In patients administered RT, there has been an observed relationship in other primary carcinomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100185DOI Listing

Orbital metastases from breast cancer: A retrospective analysis of 28 cases.

Cancer Treat Res Commun 2020 Jun 16;24:100184. Epub 2020 Jun 16.

Oncology Hospital, "Siglo XXI", National Medical Center, Mexican Institute of Social Security, Ciudad de México, Mexico.

Breast cancer account about half of the cases of orbital malignancies due to metastasis. The prognosis is adverse, with average survival from 2 to 34 months.

Objective: To analyze the clinical and pathological characteristics and outcomes of patients with orbital metastasis from breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100184DOI Listing

The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.

Cancer Treat Res Commun 2020 Jun 12;24:100183. Epub 2020 Jun 12.

City of Hope Comprehensive Cancer Center, Los Angeles, CA USA.

Since the approval of immunotherapy checkpoint inhibitors for first-line treatment of metastatic renal cell carcinoma, new and clinically relevant questions have emerged that ongoing clinical trials and trials in development will address. These questions include how to integrate combination immunotherapy approaches like ipilimumab/nivolumab with targeted therapies against vascular endothelial growth factor (VEGF) receptors, which patients can discontinue treatment, and who needs ipilimumab to maximize clinical responses. Furthermore, with new approvals of treatment regimens combining checkpoint inhibitors with targeted therapies, new questions arise in the clinic regarding optimal treatment selection for first-line clear cell renal cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100183DOI Listing

Young onset breast cancer in Southern China - a 5-year clinico-pathological study from a multi-centre database.

Cancer Treat Res Commun 2020 May 30;24:100182. Epub 2020 May 30.

Division of Breast Surgery, Department of Surgery, University of Hong Kong Hong Kong, Hong Kong SAR; Division of Breast Surgery, Department of Surgery, The University of Hong Kong Shenzhen Hospital, Shenzhen, China. Electronic address:

Aims: Breast cancer onset is known to be younger in China when compared to many westernized countries, the reason remains unknown. This study aims to evaluate the clinical and pathological characteristics of young breast cancer in Hong Kong and Shenzhen, China.

Methods: This is a 5-year retrospective review of a prospectively-maintained region-wide database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100182DOI Listing

Does muscle invasive bladder cancer following pelvic radiotherapy portend worse prognosis? A seer-based study.

Cancer Treat Res Commun 2020 May 23;24:100177. Epub 2020 May 23.

Tulane University School of Medicine, Department of Urology, 1430 Tulane Ave, New Orleans, LA 70112, USA. Electronic address:

Background: Although emerging evidence demonstrates increased risk of secondary bladder cancer following pelvic radiotherapy, the aggressiveness of these tumors is not well-characterized.

Materials And Methods: A search of the Surveillance, Epidemiology, and End Results (SEER) 18 Database, identified 25,734 patients diagnosed with bladder cancer following definitive therapy for previous pelvic malignancy. Kaplan-Meier curve analyses were utilized to determine overall survival with significance set at p<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100177DOI Listing

Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature.

Cancer Treat Res Commun 2020 May 12;24:100178. Epub 2020 May 12.

Sunnybrook Odette Cancer Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. Electronic address:

Introduction: Microglandular adenosis (MGA) is a rare benign proliferative lesion lacking a myoepithelial cell layer; 27% of all reported cases have progressed to invasive carcinoma. Salivary gland-type carcinomas of the breast are also uncommon, representing 2% of all breast cancers. This wide spectrum of neoplasms tends to be triple negative and generally has an excellent prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100178DOI Listing

A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.

Cancer Treat Res Commun 2020 Apr 20;23:100174. Epub 2020 Apr 20.

Stanford University School of Medicine, Department of Internal Medicine, Division of Oncology, Stanford Cancer Institute.

Background: A bioinformatics approach identified antitumor effects of tricyclic antidepressants (TCAs) in small cell lung cancer (SCLC) and other high-grade neuroendocrine carcinomas (grade 3 neuroendocrine carcinomas) (G3NEC) that was subsequently validated in preclinical models with a putative mechanism of action via inhibition of neuroendocrine signaling pathways. This study was undertaken to reposition the candidate TCA desipramine in a clinical trial in SCLC and G3NEC.

Methods: In this prospective, phase IIa intrapatient dose escalation clinical trial, patients were required to have failed at least one prior chemotherapy for metastatic SCLC or G3NEC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100174DOI Listing

Online information seeking behaviors of breast cancer patients before and after diagnosis: From website discovery to improving website information.

Cancer Treat Res Commun 2020 May 1;23:100176. Epub 2020 May 1.

Indiana University School of Medicine, Purdue University, West Lafayette, IN, United States.

Despite the internet being a common place breast cancer patients seek information, navigating this Wild West of content can be challenging. The present study analyzed open-ended data from breast cancer survivors (n = 77) regarding their online information seeking behaviors when looking for breast cancer information to help inform the creation of improved online educational materials. Participants were asked what prompted them to seek information, which websites and search terms they used both before and after diagnosis, what information was useful, what misinformation was found, and what they would like to see improved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100176DOI Listing

Cyclin‑dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor‑positive breast cancer patients: A systematic review and meta‑analysis of randomized clinical trials.

Cancer Treat Res Commun 2020 Apr 23;23:100175. Epub 2020 Apr 23.

Escuela de Medicina, Universidad de Costa Rica. San José, Costa Rica; Departamento de Oncología Médica, Hospital México, San José, Costa Rica.

Purpose: To compare the efficacy and safety profile of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and fulvestrant versus fulvestrant alone in previously treated patients with advanced hormone-receptor positive breast cancer.

Methods: Phase III randomized clinical trials (RCTs) were retrieved from a systematic review of electronic databases. A random-effect model was employed to determine the pooled hazard ratio (HR) for Progression-Free Survival (PFS) and Overall Survival (OS) using the inverse-variance method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100175DOI Listing

Genetic mutational analysis of β-catenin gene affecting GSK-3β phosphorylation plays a role in gallbladder carcinogenesis: Results from a case control study.

Cancer Treat Res Commun 2020 Apr 21;23:100173. Epub 2020 Apr 21.

Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005, India. Electronic address:

This manuscript has reported different mutations of β-catenin gene in gallbladder cancer patients which affect GSK-3β phosphorylation site.

Purpose: Gallbladder carcinoma (GBC) is a relatively rare and fatal cancer with poor prognosis. The molecular mechanism of gallbladder carcinogenesis is still not clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100173DOI Listing

Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma.

Cancer Treat Res Commun 2020 Mar 17;23:100172. Epub 2020 Mar 17.

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, United States. Electronic address:

The treatment landscape for renal cell cancer (RCC) has evolved tremendously over the last two decades. Treatment algorithms have shifted from the highly toxic drugs with marginal benefit to better tolerated and more effective targeted therapy drugs. The latter include tyrosine kinase inhibitors, vascular endothelial growth factor inhibitors, MET inhibitors and, more recently, immunotherapy drugs alone and in various combinations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100172DOI Listing

Diabetes mellitus type 2 is associated with increased tumor expression of programmed death-ligand 1 (PD-L1) in surgically resected non-small cell lung cancer-A matched case-control study.

Cancer Treat Res Commun 2020 Mar 5;23:100170. Epub 2020 Mar 5.

Department of Pathology and Laboratory Medicine, Penn State Hershey Medical center, 500 University Drive, Hershey, PA, United States. Electronic address:

Objectives: Programmed death-ligand 1 (PD-L1) expression is a biomarker for cancer immunotherapy. Diabetes mellitus type-2 is a comorbid disease associated with adverse outcomes in Non-Small Cell Lung Cancer (NSCLC). We aimed to investigate the differences in PD-L1 expression in diabetics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100170DOI Listing

Giant cell tumor of soft tissue of the nasopharynx: A case report.

Cancer Treat Res Commun 2020 Mar 5;23:100171. Epub 2020 Mar 5.

Section of Medical Oncology, Jose R. Reyes Memorial Medical Center, Manila, 1012, Philippines; Department of Pharmacology and Toxicology, College of Medicine, University of the Philippine Manila, Manila, 1000, Philippines. Electronic address:

Primary soft tissue giant cell tumors are rare. Although these tumors resemble their osseous counterparts, sequencing studies have suggested that these two may be genetically distinct. Treatment guidelines are less clear for this tumor type compared to giant cell tumor of the bone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100171DOI Listing

The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma.

Cancer Treat Res Commun 2020 Feb 22;23:100169. Epub 2020 Feb 22.

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, United States. Electronic address:

Treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by an expanding armamentarium of systemic therapies, which have resulted in improved patient outcomes. Multimodal approaches that include cytoreductive nephrectomy (CN), immunotherapy, and targeted therapy are necessary to optimize clinical care. Active surveillance (AS) and CN are two cornerstones of treatment in mRCC, which require reexamination in the context of new systemic therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100169DOI Listing
February 2020

Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives.

Cancer Treat Res Commun 2020 Jan 22;23:100168. Epub 2020 Jan 22.

Department of Respiratory Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.

Objectives: Patients with non-small cell lung cancer (NSCLC) may experience progression and stage shift due to delays in a complex and time-consuming diagnostic work-up. We have analyzed the impact of both a local and national intervention on total time to treatment (TTT).

Material And Methods: All patients diagnosed with NSCLC at a Norwegian county hospital from 2007 to 2016 were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100168DOI Listing
January 2020

Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung.

Cancer Treat Res Commun 2020 Jan 16;23:100167. Epub 2020 Jan 16.

Division of Medical Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, United States. Electronic address:

Neuroendocrine tumors of the lung are a diverse group of diseases with distinct pathological, molecular, and clinical characteristics. The most recent World Health Organization (WHO) classification identifies two types of high-grade neuroendocrine carcinomas of the lung: small cell lung carcinoma (SCLC), and the less common large cell neuroendocrine carcinoma of the lung (LCNEC). Systemic treatments for these aggressive tumors have largely remained unchanged for years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100167DOI Listing
January 2020

The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.

Cancer Treat Res Commun 2020 Jan 7;23:100165. Epub 2020 Jan 7.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA 02215, United States. Electronic address:

Urothelial carcinoma (UC) of the bladder and upper tract (ureter, renal pelvis) is one of the most frequently occurring malignancies. While the majority of UC are chemically induced by smoking, accumulating evidence from genetic studies have demonstrated a small, but consistent impact of heritable gene variants and family history of UC on the development of the disease. Beyond the established association between upper tract UC and germline mismatch DNA repair defects as a defining feature of Lynch syndrome, newer investigations focusing on moderate- and high-risk cancer-related gene variants in DNA damage repair and other signaling pathways are expanding our knowledge on the heritable genetic basis of UC, opening new avenues in the breadth of genetic testing and in clinical counseling of these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100165DOI Listing
January 2020

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.

Cancer Treat Res Commun 2020 Jan 7;23:100164. Epub 2020 Jan 7.

CHM, ESA - The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 201 N. Broadway, Skip Viragh Building, Baltimore, MD 21287, United States. Electronic address:

Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies aimed at old targets, and new therapies addressing new targets. This review will highlight three novel and emerging areas of treatment that have the potential to significantly impact the management of metastatic castration-resistant prostate cancer (mCRPC) in the near future: immunotherapy, poly ADP-ribose polymerase (PARP) inhibitors, and prostate-specific membrane antigen (PSMA)-targeted modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100164DOI Listing
January 2020

Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values.

Cancer Treat Res Commun 2020 Jan 3;23:100166. Epub 2020 Jan 3.

Department of Genitourinary Medical Oncology, Unit 1374, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX 77030-3721, USA. Electronic address:

The therapeutic options for advanced or metastatic renal cell carcinoma (mRCC) have drastically evolved over the past 20 years. High-dose interleukin-2 (HD IL-2), which led to durable complete responses in a small fraction of patients by activating the interleukin-2 (IL-2) pathway, faded in popularity with the advent of oral tyrosine kinase inhibitors directed against the VEGF pathway (VEGFR-TKI) showing better tolerability, wider applicability, higher objective response rates, and longer progression-free survival than HD IL-2. More recently, new insights on how to more efficiently harness the immune system led to the development of immune checkpoint inhibitor (ICI) therapies, which rapidly became an integral component of mRCC treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100166DOI Listing
January 2020

Adherence to guidelines for baseline staging in newly diagnosed localized breast cancer.

Cancer Treat Res Commun 2020 14;22:100160. Epub 2019 Sep 14.

Algoma District Cancer Program, Sault Area Hospital, Sault Ste. Marie, ON, Canada; Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada. Electronic address:

Rationale, Aims, And Objectives: Different health agencies in Canada including Cancer Care Ontario (CCO) have developed guidelines for the baseline staging of newly diagnosed breast cancer patients but adherence to them is unknown. We sought to investigate adherence to CCO staging guidelines in a single cancer center in addition to the factors that influence this adherence.

Method: A retrospective chart review was conducted on 212 newly diagnosed breast cancer patients between 2015 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100160DOI Listing
September 2019

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.

Cancer Treat Res Commun 2020 29;22:100161. Epub 2019 Sep 29.

Radiotherapy Unit, University Hospital of Parma, Parma, Italy.

Objectives: stereotactic body radiation therapy (SBRT) use has increased overtime for the management of metastatic renal cell carcinoma (mRCC) patients, with a likely good control of irradiated lesions. We planned a retrospective multicenter Italian study, with the aim of investigating the outcome of treatment with SBRT for non-brain secondary lesions in mRCC patients.

Methods: all consecutive metastatic non-brain lesions from mRCC that underwent SBRT at nine Italian institutions from January 2015 to June 2017 were considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100161DOI Listing
September 2019
1 Read

A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.

Cancer Treat Res Commun 2020 7;22:100162. Epub 2019 Oct 7.

Department of Medicine, VA Nebraska Western Iowa Health Care System, Omaha, NE, United States; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, United States; Early Phase Therapeutic Clinical Trials Unit, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address:

Background: Relapsed/refractory small cell lung cancer (SCLC) has a poor prognosis, with no good options. We evaluated a novel combination of topotecan and doxorubicin, providing sequential topoisomerase I and II inhibition, in this setting.

Materials And Methods: Adult patients (>19 years) with relapsed/refractory SCLC, who had received at least one prior chemotherapy regimen were eligible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315624PMC
October 2019

Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: A single-institute retrospective study.

Cancer Treat Res Commun 2020 29;22:100163. Epub 2019 Sep 29.

Department of Respiratory Medicine, Kumamoto Regional Medical Center, 5-16-10 Honjo, Kumamoto 860-0811, Japan.

Introduction: In EGFR-mutant NSCLC patients with oligo-progression disease (oligo-PD) after the EGFR-TKI failure, additional local ablative therapy (LAT) including stereotactic ablative radiotherapy reportedly extends the duration of the current EGFR-TKI and prolongs survival times. In clinical practice, however, all the patients cannot receive LAT for oligo-PD.

Methods: We retrospectively evaluated the efficacy and tolerability of additional bevacizumab as an alternative to LAT for oligo-PD after the EGFR-TKI failure in previously treated lung adenocarcinoma patients (median number of previous therapies, 2 regimens). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100163DOI Listing
September 2019
1 Read

Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC).

Cancer Treat Res Commun 2019 5;21:100158. Epub 2019 Sep 5.

Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195, Little Albany street, New Brunswick, NJ 08903, USA.

Objectives: Activation of cell survival pathways such as autophagy represents a potential resistance mechanism to chemotherapy in NSCLC. Preclinical studies report that autophagy inhibition suppresses lung tumor development and progression. We report the safety and efficacy for adding autophagy inhibitor, hydroxychloroquine, to chemotherapy in a phase Ib/II single-arm study in patients with metastatic NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100158DOI Listing
June 2020
1 Read

Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma.

Cancer Treat Res Commun 2019 5;21:100159. Epub 2019 Sep 5.

Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Background: Dysregulated bone turnover is an important clinical manifestation of multiple myeloma (MM), and 30% of patients present with hypercalcemia. Serum calcium levels are routinely monitored using total calcium measurements corrected for albumin. However, myeloma-related paraproteins may bind calcium, confounding these measurements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100159DOI Listing
June 2020
3 Reads

Evaluation of cytotoxic activity of docetaxel loaded gold nanoparticles for lung cancer drug delivery.

Cancer Treat Res Commun 2019 10;21:100157. Epub 2019 Jul 10.

Nano-Bio Materials and Sensors Laboratory, National Centre for Nanoscience and Nanotechnology, University of Madras, Guindy Campus, Chennai 600025, India. Electronic address:

The effective use of the gold nanoparticle (AuNPs) conjugated drugs for targeted drug delivery applications is one of the most promising research areas in the field of cancer. Herein, we aimed to establish a nano drug conjugated with docetaxel as a possible therapy option. Gold nanoparticles were synthesized by chemical reduction method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100157DOI Listing

Association between long-term NSAID use and opioid abuse among patients with breast cancer.

Cancer Treat Res Commun 2019 2;21:100156. Epub 2019 Jul 2.

Department of Surgery, Howard University College of Medicine, Washington, DC, United States.

Background: Improving survival rates among patients with breast cancer has been associated with an increase in the prevalence of co-morbidities like cancer-related pain. Opioids are an important component in the management of pain among these patients. However, the progression from judicious use to abuse defeats the aim of pain control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100156DOI Listing
June 2020
4 Reads

Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Cancer Treat Res Commun 2019 3;21:100155. Epub 2019 Jul 3.

Department of Medical Oncology & Therapeutics Research, City of Hope National Cancer Center, Duarte, CA, United States. Electronic address:

Background: Oral metronomic chemotherapy, which has low toxicity, has demonstrated promising anti-tumor and anti-angiogenic properties that may lead to prolonged progression-free survival and improved response rates in patients with recurrent epithelial ovarian cancer (EOC). These effects may be enhanced by the co-administration of anti-angiogenic agents.

Methods: We conducted a randomized phase II clinical trial to evaluate the therapeutic benefit of oral metronomic cyclophosphamide (CTX) alone and with the anti-angiogenic drug celecoxib in patients with gynecological malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100155DOI Listing
June 2020
7 Reads

Questions about the primary tumor resection for de-novo metastatic breast cancers.

Authors:
Kadri Altundag

Cancer Treat Res Commun 2019 ;20:100131

MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100131DOI Listing
October 2019
2 Reads

Long term survival study of de-novo metastatic breast cancers with or without primary tumour resection.

Cancer Treat Res Commun 2019 ;20:100148

Department of Surgery, Queen Mary Hospital, Hong Kong, Hong Kong Special Administrative Region; Department of Surgery, Tung Wah Hospital, Hong Kong, Hong Kong Special Administrative Region; Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100148DOI Listing
October 2019
1 Read

Expression of micrornas in molecular genetic breast cancer subtypes.

Cancer Treat Res Commun 2019 20;20:100026. Epub 2016 Aug 20.

Institute of Molecular and Cell Biology, Novosibirsk 630090, Russia. Electronic address:

Background: It is shown that each type of human malignancies has a unique set of expressed miRNAs, and tumor-specific miRNAs in biological tissues of a patient are stable. The aim of this study was to determine the differences in the expression of miRNAs in tumor tissue of invasive breast carcinoma compared to normal tissue, as well as to analyze the variable expression of miRNAs in molecular genetic subtypes of breast cancer.

Methods: We determined differences in mRNA expression in 35 biopsies of tumor tissue of various molecular genetic subtypes of breast cancer and 35 biopsies of adjacent conventionally normal breast tissue by RT-PCR in real time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2016.08.006DOI Listing
February 2020
4 Reads

Trainees' knowledge and application of guideline recommendations for colorectal cancer screening and surveillance.

Cancer Treat Res Commun 2019 11;21:100153. Epub 2019 Jun 11.

Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH, USA. Electronic address:

Background: Data shows that practicing physicians don't recommend colorectal (CRC) screening and surveillance as suggested by guidelines. We assessed knowledge of CRC guidelines in medical trainees.

Methods: A survey assessing confidence and knowledge of published CRC guidelines was emailed to program directors (PDs) of Accreditation Council of Graduate Medical Education approved training programs in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100153DOI Listing
June 2020
14 Reads

Ovarian carcinomas express HE4 epitopes independently of each other.

Cancer Treat Res Commun 2019 24;21:100152. Epub 2019 May 24.

Department of Pathology, University of Washington, Harborview Medical Center Seattle, 325 9th Ave, Box 359939, Seattle, WA 98104, United States.

Background: The gene encoding HE4 undergoes alternative splicing to yield multiple protein isoforms. We investigated anti-HE4 mAbs which recognize epitopes on the C (2H5 and 3D8) or N (12A2 and 14E2) terminals.

Methods: A Luminex assay was applied to determine mAb affinity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100152DOI Listing
June 2020
12 Reads

Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review.

Cancer Treat Res Commun 2019 11;21:100154. Epub 2019 Jun 11.

Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Purpose: Sarcopenia has been considered a poor prognostic factor in various malignant diseases. However, the studies that evaluated the association between CT-determined sarcopenia and outcome in breast cancer patients reported different results. Therefore, the aim of the present study is to perform a systematic review of the current literature on the evaluation of body CT-determined sarcopenia in breast cancer patients, focusing on the correlation with outcome values. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100154DOI Listing
June 2020
13 Reads

Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer.

Cancer Treat Res Commun 2019 14;20:100151. Epub 2019 May 14.

Tulane Cancer Center, Tulane University School of Medicine, 150 S Liberty St, New Orleans, LA 70112, Unites States; Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112, Unites States. Electronic address:

Background: Prostate cancer patients with liver metastases have a poor prognosis. To date, no study exists investigating the relationship between liver tumor burden and clinical laboratory markers.

Materials And Methods: Metastatic castrate-resistant prostate cancer (mCRPC) patients with radiographic evidence of liver metastases were selected for this study. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24682942183013
Publisher Site
http://dx.doi.org/10.1016/j.ctarc.2019.100151DOI Listing
February 2020
13 Reads

A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer.

Cancer Treat Res Commun 2019 10;20:100150. Epub 2019 May 10.

Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington, DC, USA.

Background: Despite a wealth of preclinical and observational data, prospective data regarding the use of metformin in lung cancer is extremely limited.

Methods: We pooled individualized data from two prospective trials evaluating metformin plus platinum-based chemotherapy, with or without bevacizumab, in non-diabetic patients with untreated advanced NSCLC. In addition to reporting on clinical efficacy and safety endpoints, we also explored metformin's activity in key molecular cohorts. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24682942193004
Publisher Site
http://dx.doi.org/10.1016/j.ctarc.2019.100150DOI Listing
February 2020
31 Reads

ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective.

Cancer Treat Res Commun 2019 1;20:100149. Epub 2019 May 1.

Department of Internal Medicine, Division of Hematology/Oncology, Loma Linda University, Loma Linda, CA, United States. Electronic address:

Anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) is diagnosed in up to 126,000 patients worldwide annually. Ceritinib is a next-generation ALK-targeted tyrosine kinase inhibitor that is approved for the treatment of patients with metastatic ALK+ NSCLC. In December 2017, the US Food and Drug Administration-approved dose of ceritinib was changed from 750 mg/day under fasting conditions to 450 mg/day taken with food for the treatment of patients with ALK+ NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100149DOI Listing
February 2020
1 Read

Economic disparities in Appalachia linked to risk factors for long-term health for estrogen positive breast cancer patients.

Cancer Treat Res Commun 2019 14;19:100128. Epub 2019 Mar 14.

Department of Human Ecology, University of California, Davis, One Shield Avenue, Davis, CA 95616, United States.

Background: Breast cancer is the second leading cause of cancer death for women in the United States and mortality from cancer is more common among individuals in the Appalachian region compared to the rest of the country. We examined how risk factors for long-term health outcomes for Estrogen positive breast cancer patients differed by county economic status in southern Appalachia.

Methods: Data was collected through retrospective data mining of patient medical files (N = 238). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100128DOI Listing
September 2019

Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.

Cancer Treat Res Commun 2019 23;19:100130. Epub 2019 Mar 23.

Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada; Ottawa Hospital Cancer Centre, Ottawa, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada; Ottawa Hospital Research Institute, 725 Parkdale Avenue, Ottawa, Ontario K1Y4E9, Canada. Electronic address:

Background: Most newly diagnosed advanced NSCLC patients have an initial medical oncology consult as an outpatient. Sometimes, the initial consult occurs as an inpatient. We explored differences among NSCLC patients presenting to medical oncology while hospitalized versus as outpatients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100130DOI Listing
September 2019
2 Reads

Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.

Cancer Treat Res Commun 2019 14;19:100127. Epub 2019 Mar 14.

Centre for Cancer Biomarkers, University of Bergen, Norway; Department of Oncology, Haukeland University Hospital, Bergen, Norway. Electronic address:

Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common type among renal cell carcinomas, and anti-angiogenic treatment is currently first line therapy in metastatic ccRCC (mccRCC). Response rates and duration of response show considerable variation, and adverse events have major influence on patient's quality of life. The need for predictive biomarkers to select those patients most likely to respond to receptor tyrosine kinase inhibitors (rTKI) upfront is urgent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100127DOI Listing
September 2019
4 Reads

Hepatocellular carcinoma: Clinical-pathological features and HIV infection in Mozambican patients.

Cancer Treat Res Commun 2019 16;19:100129. Epub 2019 Mar 16.

Unité « Organisation Nucléaire et Oncogenèse », INSERM U993, Institut Pasteur, Paris, France.

Background And Aims: Mozambique had been ranked among the countries with the highest global incidence of HCC with chronic hepatitis B infection and high exposure to aflatoxin-B1 (AFB1) being major risk factors. Indeed, HCC remains one of the most frequent cancer in Maputo. On the other hand, Mozambique has a high prevalence of infection with Human Immunodeficiency virus (HIV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504939PMC
September 2019
8 Reads

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

Cancer Treat Res Commun 2019 26;19:100126. Epub 2019 Feb 26.

Lineberger Cancer Center at the University of North Carolina, 170 Manning Drive, Room 3115, Campus Box 7305, Chapel Hill, NC 27514, United States. Electronic address:

Introduction: Retrospective studies have evaluated the approach of stereotactic radiotherapy (SRT) to address oligoprogression in patients with EGFR mutant NSCLC on TKI therapy, it has never been prospectively studied.

Materials And Methods: We treated 25 patients with EGFR mutant NSCLC on erlotinib who had 3 or fewer sites of extra-cranial progression with SRT to progressing sites, followed by re-initiation of erlotinib.

Results: Median PFS from the initiation of SRT was 6 months (95% CI 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100126DOI Listing
September 2019
2 Reads

Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.

Cancer Treat Res Commun 2019 19;19:100124. Epub 2019 Feb 19.

Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Largo Brambilla n.3, 50134, Florence, Italy. Electronic address:

Urothelial cancer is one of the most common malignancies; after relapse or disease progression available therapeutic options are limited. We analyze efficacy and toxicity of local treatment on metastases using stereotactic body radiation therapy (SBRT) in selected patients with oligometastatic disease from urothelial cancer. A significant percentage of treated lesions achieved local control, with a promising overall response rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100124DOI Listing
September 2019
2 Reads

The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).

Cancer Treat Res Commun 2019 21;19:100123. Epub 2019 Feb 21.

Multidisciplinary Breast Clinic of Antwerp, University Hospital of Antwerp, Wilrijkstraat 10. Antwerp 2650, Belgium; Faculty of Medicine, University of Antwerp, Antwerp, Belgium; Unit of Gynecologic Oncology, Department of Obstetrics & Gynecology, University Hospital of Antwerp, Antwerp, Belgium.

Background: Breast cancer has, due its high incidence, the highest mortality of cancer in women. The most common molecular variety of breast cancer is luminal subtype that expresses estrogen and progesterone receptors. Estrogen receptor alpha (ERα), encoded by the estrogen receptor1 (ESR1) gene, is expressed in approximately 70% of all breast cancers, and hormonal therapy represents a major treatment modality in all stages of ER positive breast cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100123DOI Listing
September 2019
18 Reads

De-novo metastatic breast cancers with or without primary tumor resection - A 10-year study.

Cancer Treat Res Commun 2019 21;19:100118. Epub 2019 Jan 21.

Department of Surgery, Queen Mary Hospital, Hong Kong; Department of Surgery, The University of Hong Kong, Hong Kong. Electronic address:

Background: Treatment of de novo metastatic breast cancer is usually palliative with systemic treatment; surgical excision of the primary tumour is reserved in patients with significant symptoms from the primary tumour. Survival benefit of surgical removal of the primary tumour remains controversial.

Methods: All patients treated with de novo metastatic breast cancer (MBC) between 2007 and 2016 were retrieved from a prospectively-maintained database. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24682942183008
Publisher Site
http://dx.doi.org/10.1016/j.ctarc.2019.100118DOI Listing
September 2019
6 Reads

Diagnostic utility of epigenetics in breast cancer - A review.

Cancer Treat Res Commun 2019 19;19:100125. Epub 2019 Feb 19.

Government Medical College, Srinagar, Jammu & Kashmir, India.

Epigenetic alterations are clearly involved in cancer initiation and progression as recent epigenetic studies of genomic DNA, histone modifications and micro-RNA alterations suggest that these are playing an important role in the incidence of breast cancer. Epigenetic information has recently gained the attention of researchers because epigenetic modification of the genome in breast cancer is still an evolving area for researchers. Several active compounds present in foods, poisons, drugs, and industrial chemicals may as a result of epigenetic mechanisms increase or decrease the risk of breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100125DOI Listing
September 2019
1 Read

Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.

Cancer Treat Res Commun 2019 6;19:100121. Epub 2019 Feb 6.

West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, United States.

Purpose: This retrospective study of community oncology patients with breast cancer gene (BRCA)-mutated metastatic breast cancer (MBC) examined treatment outcomes and health resource utilization (HRU) and costs for a sample of patients with human epidermal growth factor receptor 2 (HER2)-negative disease who were either hormone receptor positive (HR+) or triple negative breast cancer (TNBC).

Methods: Evidence from the Vector Oncology Data Warehouse, a repository of electronic medical records/billing data and provider notes, was analyzed. Treatment outcomes were progression-free survival (PFS) and overall survival (OS) from start of first-line therapy in the metastatic setting. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24682942183013
Publisher Site
http://dx.doi.org/10.1016/j.ctarc.2019.100121DOI Listing
September 2019
13 Reads